Q-omics provides the consensus-scored MIR33A profile across patient tissues and cancer cell-line models. MIR33A expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR33A is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, MIR33A RNA expression shows 8,292 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight ACC, KICH, and SARC as cancer lineages where MIR33A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR33A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR33A survival associations across molecular data types. MIR33A RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR33A RNA expression–survival associations across cancer types. High MIR33A expression shows unfavorable associations in ACC, READ, COAD, THCA, KIRP and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR33A RNA expression.
This table summarizes MIR33A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR33A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR33A shows higher tumor expression in KICH. The KICH box plot shows higher MIR33A RNA expression in tumor versus normal tissue (log2 FC = +0.191, t-test p = .028).
This table shows molecular features associated with MIR33A in patient tissues and cancer cell lines. In patient samples, MIR33A shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
